KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Income from Continuing Operations (2016 - 2025)

Sarepta Therapeutics has reported Income from Continuing Operations over the past 15 years, most recently at 352818000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 122.23% year-over-year to 352818000.0; the TTM value through Dec 2025 reached 77701000.0, down 133.07%, while the annual FY2025 figure was 77711000.0, 133.07% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 352818000.0 at Sarepta Therapeutics, up from 179949000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 352818000.0 in Q4 2025 and troughed at 516710000.0 in Q1 2023.
  • A 5-year average of 29848150.0 and a median of 32438500.0 in 2023 define the central range for Income from Continuing Operations.
  • On a YoY basis, Income from Continuing Operations climbed as much as 2940.57% in 2025 and fell as far as 1338.98% in 2025.
  • Year by year, Income from Continuing Operations stood at 249334000.0 in 2021, then plummeted by 42.99% to 142140000.0 in 2022, then surged by 130.0% to 326928000.0 in 2023, then tumbled by 51.44% to 158759000.0 in 2024, then soared by 122.23% to 352818000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SRPT at 352818000.0 in Q4 2025, 179949000.0 in Q3 2025, and 196938000.0 in Q2 2025.